ATE530174T1 - Beta-2 adrenergische agonisten zur behandlung von chronischer neuropatischer allodynie - Google Patents
Beta-2 adrenergische agonisten zur behandlung von chronischer neuropatischer allodynieInfo
- Publication number
- ATE530174T1 ATE530174T1 AT09720431T AT09720431T ATE530174T1 AT E530174 T1 ATE530174 T1 AT E530174T1 AT 09720431 T AT09720431 T AT 09720431T AT 09720431 T AT09720431 T AT 09720431T AT E530174 T1 ATE530174 T1 AT E530174T1
- Authority
- AT
- Austria
- Prior art keywords
- allodynia
- beta
- treatment
- field
- chronic
- Prior art date
Links
- 208000004454 Hyperalgesia Diseases 0.000 title abstract 3
- 206010053552 allodynia Diseases 0.000 title abstract 3
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- 208000002193 Pain Diseases 0.000 abstract 2
- 230000002981 neuropathic effect Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000808 adrenergic beta-agonist Substances 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800273A FR2926464B1 (fr) | 2008-01-18 | 2008-01-18 | Composes utilisables pour le traitement de douleurs neuropathiques |
| EP08003458 | 2008-02-26 | ||
| EP08291065 | 2008-11-14 | ||
| PCT/FR2009/000045 WO2009112674A2 (fr) | 2008-01-18 | 2009-01-16 | Composes utilisables pour le traitement de douleurs neuropathiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530174T1 true ATE530174T1 (de) | 2011-11-15 |
Family
ID=41065598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09720431T ATE530174T1 (de) | 2008-01-18 | 2009-01-16 | Beta-2 adrenergische agonisten zur behandlung von chronischer neuropatischer allodynie |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110027352A1 (de) |
| EP (1) | EP2252278B1 (de) |
| JP (1) | JP2011509981A (de) |
| AT (1) | ATE530174T1 (de) |
| CA (1) | CA2715110A1 (de) |
| ES (1) | ES2375924T3 (de) |
| WO (1) | WO2009112674A2 (de) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0181285B1 (de) | 1984-11-05 | 1989-04-19 | Karl Vollenweider | Anschlussverbindung für vorwiegend Halbhohl- und Hohlprofile |
| FR2740040B1 (fr) * | 1995-10-23 | 1997-12-05 | Oreal | Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p |
| AU2003280117B2 (en) * | 2002-11-20 | 2009-09-10 | Newron Sweden Ab | Compounds and methods for increasing neurogenesis |
| US7474933B2 (en) | 2003-07-14 | 2009-01-06 | Esilicon Corporation | System and method for automating integration of semiconductor work in process updates |
| US7550466B2 (en) * | 2003-08-27 | 2009-06-23 | Sun Health Research Institute | Alpha and/or β-adrenergic antagonists and agonists to treat pain |
| US7462618B2 (en) * | 2003-08-27 | 2008-12-09 | Sun Health Research Institute | Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists |
| AU2005224160A1 (en) * | 2004-03-17 | 2005-09-29 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain using beta-aminoalcohols |
| CA2579540A1 (en) | 2004-09-07 | 2006-03-16 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain |
| CA2589001A1 (en) * | 2004-11-19 | 2006-05-26 | Kissei Pharmaceutical Co., Ltd. | Preventive or therapeutic agent for neuropathic pain |
| GB0513297D0 (en) * | 2005-06-29 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| US20090325975A1 (en) * | 2005-07-15 | 2009-12-31 | Helmut H Buschmann | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
-
2009
- 2009-01-16 EP EP09720431A patent/EP2252278B1/de not_active Not-in-force
- 2009-01-16 JP JP2010542662A patent/JP2011509981A/ja active Pending
- 2009-01-16 US US12/863,380 patent/US20110027352A1/en not_active Abandoned
- 2009-01-16 ES ES09720431T patent/ES2375924T3/es active Active
- 2009-01-16 AT AT09720431T patent/ATE530174T1/de not_active IP Right Cessation
- 2009-01-16 WO PCT/FR2009/000045 patent/WO2009112674A2/fr active Application Filing
- 2009-01-16 CA CA2715110A patent/CA2715110A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110027352A1 (en) | 2011-02-03 |
| CA2715110A1 (fr) | 2009-09-17 |
| ES2375924T3 (es) | 2012-03-07 |
| EP2252278B1 (de) | 2011-10-26 |
| WO2009112674A3 (fr) | 2009-12-10 |
| JP2011509981A (ja) | 2011-03-31 |
| EP2252278A2 (de) | 2010-11-24 |
| WO2009112674A2 (fr) | 2009-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY147864A (en) | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | |
| ATE454140T1 (de) | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität | |
| PL385586A1 (pl) | Nowe analogi insuliny o przedłużonym działaniu | |
| PH12013501790B1 (en) | Use of dpp iv inhibitors | |
| MY156285A (en) | Co-crystals of tramadol and coxibs | |
| MX338512B (es) | Dispositivo para tratamiento médico y/o cosmético. | |
| DE602007004615D1 (de) | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen | |
| ATE446744T1 (de) | Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit | |
| BR112012006010A2 (pt) | composto de glicina | |
| IN2012DN04918A (de) | ||
| ATE525084T1 (de) | Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus | |
| UA81573C2 (en) | Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients | |
| MX2010001449A (es) | Bromhidrato de bupropion y aplicaciones terapeuticas. | |
| GEP20196969B (en) | New therapeutical composition containing apomorphine as active ingredient | |
| MY143269A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder | |
| EP2490700A4 (de) | Externe hautzusammensetzung mit einem salz und einem zucker als wirkstoffen zur prophylaxe und behandlung von vaginose und verwendung davon | |
| RU2013132566A (ru) | Терапевтическое средство от грыжи межпозвоночного диска | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении | |
| EA201591793A1 (ru) | Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний | |
| EA201390345A1 (ru) | Терапевтическое болеутоляющее средство | |
| WO2009131850A3 (en) | Pai-1 expression and activity inhibitors for the treatment of ocular disorders | |
| ATE530174T1 (de) | Beta-2 adrenergische agonisten zur behandlung von chronischer neuropatischer allodynie | |
| UA99638C2 (ru) | Оксазолидиноны для лечения и/или профилактики сердечной недостаточности | |
| MX2013006031A (es) | Formulacion liposomal de dalcetrapib. | |
| TNSN07364A1 (en) | Use of agomelatine for obtaining medicaments used for treating bipolar disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |